Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1 Lung Neoplasms 1 Brain Neoplasms 1

Interventions

Radiotherapy 39 pembrolizumab 37 Carboplatin 37 Cisplatin 34 Paclitaxel 26 Pemetrexed 24 Docetaxel 18 Nivolumab 17 Magnetic Resonance Spectroscopy 17 Gemcitabine 17 Bevacizumab 17 Specimen Handling 16 Cyclophosphamide 15 osimertinib 14 Radiation 13 Irinotecan 13 Etoposide 13 Erlotinib Hydrochloride 12 durvalumab 11 Topotecan 10 Cetuximab 10 Radiosurgery 9 Immunoglobulin G 8 Fluorouracil 8 Everolimus 8 Disulfides 8 Celecoxib 8 fludarabine 7 Taxes 7 Ipilimumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lung Neoplasms × tepotinib × Clear all

NCT05782361 2026-04-24

POTENT

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡